Eurofins: share price down sharply, broker adjusts his advice
Acknowledging that Eurofins shares have had a difficult 2022, the broker believes that the challenges facing the bio-analysis provider 'could continue into 2023' and sees a risk to consensus in terms of near-term results.
'The risk associated with the French diagnostics budget, laboratory strikes, combined with continued cost inflation and a gloomy outlook for pharmaceutical and food testing, prompt us to become more cautious', he explains.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction